Check Out What Whales Are Doing With ABBV
Check Out What Whales Are Doing With ABBV
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.
金融巨頭在艾伯維公司上展現出明顯的看好動作。我們對艾伯維公司（NYSE:ABBV）期權歷史的分析顯示出了13筆異常交易。
Delving into the details, we found 46% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $276,786, and 6 were calls, valued at $363,437.
深入了解細節後，我們發現46%的交易員持有看好態度，而30%顯示出看跌傾向。在我們發現的所有交易中，有7筆看跌交易，價值爲276,786美元，有6筆看漲交易，價值爲363,437美元。
What's The Price Target?
目標價是多少？
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $200.0 for AbbVie over the recent three months.
根據交易活動，顯然重要投資者正瞄準艾伯維公司在最近三個月內價格區間從150.0美元至200.0美元的目標價位。
Volume & Open Interest Trends
成交量和未平倉量趨勢
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
這些數據可以幫助您跟蹤Coinbase Glb期權的流動性和利益，以給定的行權價格爲基礎。
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
這些數據可以幫助您跟蹤AbbVie期權的流動性和興趣，以獲得給定的行權價格。
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $150.0 to $200.0 in the last 30 days.
下面，我們可以觀察到過去30天內，針對艾伯維公司所有涉及期權執行價範圍在150.0美元至200.0美元之間的大宗交易活動的看漲和看跌的成交量和未平倉合約的演變。
AbbVie Call and Put Volume: 30-Day Overview
艾伯維公司看漲和看跌成交量：30天總覽
Largest Options Trades Observed:
觀察到的最大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | CALL | TRADE | BULLISH | 01/17/25 | $20.05 | $19.6 | $19.87 | $160.00 | $135.1K | 2.9K | 71 |
| ABBV | CALL | TRADE | BULLISH | 08/15/25 | $24.55 | $24.3 | $24.55 | $160.00 | $68.7K | 43 | 28 |
| ABBV | CALL | SWEEP | BULLISH | 12/20/24 | $1.74 | $1.63 | $1.64 | $182.50 | $50.6K | 716 | 499 |
| ABBV | PUT | SWEEP | BEARISH | 06/20/25 | $9.6 | $9.4 | $9.6 | $175.00 | $48.0K | 1.3K | 67 |
| ABBV | PUT | SWEEP | BULLISH | 01/16/26 | $6.85 | $6.45 | $6.42 | $150.00 | $46.9K | 830 | 299 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | 看漲 | 交易 | BULLISH | 01/17/25 | $20.05 | $19.6 | $19.87 | $160.00 | $135.1K | 2.9K | 71 |
| ABBV | 看漲 | 交易 | BULLISH | 08/15/25 | $24.55 | $24.3 | $24.55 | $160.00 | $68.7K | 43 | 28 |
| ABBV | 看漲 | SWEEP | BULLISH | 12/20/24 | $1.74 | $1.63 | $1.64 | $182.50 | $50.6K | 716 | 499 |
| ABBV | 看跌 | SWEEP | 看淡 | 06/20/25 | 9.6 | $9.4 | 9.6 | $175.00 | $48.0千 | 1.3千 | 67 |
| ABBV | 看跌 | SWEEP | BULLISH | 01/16/26 | $6.85 | $6.45 | $6.42 | $150.00 | $46.9K | 830 | 299 |
About AbbVie
關於艾伯維公司
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie是一家藥品公司，其在免疫學（包括Humira、Skyrizi和Rinvoq）和腫瘤學（包括Imbruvica和Venclexta）方面擁有強大的業務。該公司於2013年初從Abbott分拆而來。2020年收購雅培使其在美容業務（包括Botox）中新增了一些產品和藥品。
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考慮到艾伯維公司最近的期權歷史，現在是時候專注於公司本身了。我們的目標是探討其當前的表現。
Where Is AbbVie Standing Right Now?
艾伯維目前處於什麼狀態？
- Trading volume stands at 2,777,110, with ABBV's price down by -2.71%, positioned at $176.59.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 58 days.
- 交易量爲2,777,110，ABBV的價格下跌-2.71%，位於176.59美元。
- RSI指標顯示該股票目前處於超買和超賣之間的中立狀態。
- 預計在58天內公佈收益報告。
What The Experts Say On AbbVie
艾伯維公司專家意見
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $212.8.
在過去的一個月中，5位行業分析師分享了對這隻股票的見解，提出了平均目標價爲212.8美元。
Turn $1000 into $1270 in just 20 days?
在短短20天內，將1000美元變成1270美元？
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.* Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $206. * Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on AbbVie with a target price of $208. * Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $224. * An analyst from Wolfe Research downgraded its action to Outperform with a price target of $205. * An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $221.
20年的期權交易專家揭示了他的一行圖表技術，顯示何時買入和賣出。複製他的交易，平均每20天實現27%的利潤。點擊這裏獲取。* 展現樂觀態度，Leerink Partners的一位分析師將其評級提升爲表現優異，並將目標價修訂爲206美元。* 在評估中保持一貫性，BMO Capital的一位分析師對艾伯維公司保持表現優異的評級，目標價爲208美元。* 在維持他們的立場，摩根士丹利的一位分析師繼續對艾伯維公司保持超配評級，目標價爲224美元。* Wolfe Research的一位分析師將其評級下調爲表現優異，並設定目標價爲205。* 古根海姆的一位分析師堅持對艾伯維公司的買入評級，並保持目標價爲221美元。
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.
期權交易涉及更大的風險，但也提供了更高利潤的潛力。精明的交易員通過持續的教育、戰略交易調整、利用各種因子，並保持對市場動態的敏銳感來減輕這些風險。通過Benzinga Pro保持最新的艾伯維公司期權交易，即時獲得警報。
譯文內容由第三人軟體翻譯。